FDA Panel Backs Four Peptides for the 503 List

Builderman

Builderman

Explorer
Joined
Apr 24, 2026
Messages
112
Reaction score
0
Location
Utah
Good news that the FDA committee today came out in favour of adding BPC-157, TB500, KPV, and Mots-C to the 503 bulk drug substance list. That looks like movement in the right direction. My own sourcing won't change over it, but if the fda does end up approving on the back of these recommendations, I would hope we see more human trials for them.

How realistic is it to expect more human trials once FDA approval is given?
 
Builderman said:

Good news that the FDA committee today came out in favour of adding BPC-157, TB500, KPV, and Mots-C to the 503 bulk drug substance list. That looks like movement in the right direction. My own sourcing won't change over it, but if the fda does end up approving on the back of these recommendations, I would hope we see more human trials for them.

How realistic is it to expect more human trials once FDA approval is given?
Click to expand...
That will not happen with the human trials, it is not the fda's job. And on approval, these were already approved years back until 2022.
 
When the FDA reckons they are a good idea, that makes me wonder whether I ought to keep taking them at all...
 
CNCCurrency said:

Builderman said:

Good news that the FDA committee today came out in favour of adding BPC-157, TB500, KPV, and Mots-C to the 503 bulk drug substance list. That looks like movement in the right direction. My own sourcing won't change over it, but if the fda does end up approving on the back of these recommendations, I would hope we see more human trials for them.

How realistic is it to expect more human trials once FDA approval is given?
Click to expand...
That will not happen with the human trials, it is not the fda's job. And on approval, these were already approved years back until 2022.
Click to expand...
Interesting, that is news to me. My understanding was that these were sometimes used in the past but never fda approved and never formally placed on the 503.
 
Vash said:

When the FDA reckons they are a good idea, that makes me wonder whether I ought to keep taking them at all...
Click to expand...
Fair enough I suppose, I do understand it. Then again, Tirzepatide is fda approved, and Reta more than likely will be sometime in 2027, so their approval won't stop me even for a second from taking them.
 
Builderman said:

Vash said:

When the FDA reckons they are a good idea, that makes me wonder whether I ought to keep taking them at all...
Click to expand...
Fair enough I suppose, I do understand it. Then again, Tirzepatide is fda approved, and Reta more than likely will be sometime in 2027, so their approval won't stop me even for a second from taking them.
Click to expand...
Apologies, never switched the sarcasm font on...
 
Builderman said:

Good news that the FDA committee today came out in favour of adding BPC-157, TB500, KPV, and Mots-C to the 503 bulk drug substance list. That looks like movement in the right direction. My own sourcing won't change over it, but if the fda does end up approving on the back of these recommendations, I would hope we see more human trials for them.

How realistic is it to expect more human trials once FDA approval is given?
Click to expand...
Curious how we are meant to anticipate what this does to price and or availability for those of us who would rather keep taking our chances on black/grey market?!
 
IssyAssaySissa said:

Builderman said:

Good news that the FDA committee today came out in favour of adding BPC-157, TB500, KPV, and Mots-C to the 503 bulk drug substance list. That looks like movement in the right direction. My own sourcing won't change over it, but if the fda does end up approving on the back of these recommendations, I would hope we see more human trials for them.

How realistic is it to expect more human trials once FDA approval is given?
Click to expand...
Curious how we are meant to anticipate what this does to price and or availability for those of us who would rather keep taking our chances on black/grey market?!
Click to expand...
Hard to say. Possibly cheaper on grey if people move over to compounded. Competition lowers prices.
 
CNCCurrency said:

IssyAssaySissa said:

Builderman said:

Good news that the FDA committee today came out in favour of adding BPC-157, TB500, KPV, and Mots-C to the 503 bulk drug substance list. That looks like movement in the right direction. My own sourcing won't change over it, but if the fda does end up approving on the back of these recommendations, I would hope we see more human trials for them.

How realistic is it to expect more human trials once FDA approval is given?
Click to expand...
Curious how we are meant to anticipate what this does to price and or availability for those of us who would rather keep taking our chances on black/grey market?!
Click to expand...
Hard to say. Possibly cheaper on grey if people move over to compounded. Competition lowers prices.
Click to expand...
Great! Fingers crossed that turns out to be right!
 
What the committee said is eye opening. As far as I can tell the case put to a room of doctors was simply that people (us) are doing it anyway. So this is what American science looks like in 2026?
 
My understanding was that this panel only recommends. The final word belongs to the FDA, so nothing is settled yet. Their (FDA) comments didn't come across as supportive.
 
moodymama76 said:

My understanding was that this panel only recommends. The final word belongs to the FDA, so nothing is settled yet. Their (FDA) comments didn't come across as supportive.
Click to expand...
What the fda said was not promising. In the past the agency has tended to follow what these panels vote for, so their eventual decision will be worth watching.
 
Back
Top